![Gregory W. Schafer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gregory W. Schafer
Nessuna posizione attualmente
Storia della carriera di Gregory W. Schafer
Precedenti posizioni note di Gregory W. Schafer
Società | Posizione | Inizio | Fine |
---|---|---|---|
CHINOOK THERAPEUTICS, INC. | Direttore operativo | 23/07/2013 | 01/03/2018 |
Public Communications Contact | 23/07/2013 | 31/03/2015 | |
CAPRICOR THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 20/11/2013 | 02/06/2016 |
Independent Dir/Board Member | 20/11/2013 | 02/06/2016 | |
SillaJen Biotherapeutics, Inc.
![]() SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Direttore Finanziario/CFO | 23/06/2010 | 01/07/2013 |
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Direttore Finanziario/CFO | 01/01/2006 | 15/12/2008 |
IntraBiotics Pharmaceuticals, Inc.
![]() IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Direttore Finanziario/CFO | - | 19/08/2005 |
CERUS CORPORATION | Direttore Finanziario/CFO | 01/01/1997 | 01/01/2004 |
Deloitte & Touche LLP
![]() Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
Formazione di Gregory W. Schafer
University of Pennsylvania | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 10 |
Posizioni
Director of Finance/CFO | 4 |
Undergraduate Degree | 1 |
Director/Board Member | 1 |
Settori
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
CERUS CORPORATION | Health Technology |
CAPRICOR THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
IntraBiotics Pharmaceuticals, Inc.
![]() IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
SillaJen Biotherapeutics, Inc.
![]() SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Aduro BioTech, Inc.
![]() Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Deloitte & Touche LLP
![]() Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
- Borsa valori
- Insiders
- Gregory W. Schafer
- Esperienza